Currently resident in the Technology Incubation Program at the University of Connecticut, Nami Therapeutics Corporation personnel are structured around developing specifically designed nanoparticles for the targeted delivery of therapeutic agents, including radio-therapeutics, to tumors. Using technologies licensed from the University of Connecticut and the University of North Carolina, the Nami team are academics with over 50 years of collective experience in the drug delivery field. The objective is to advance the firm's nanotechnology-based products to the clinical trial stage by demonstrating the efficacy of its products in preclinical models, and by completing IND enabling activities such as manufacturing process development (CMC) and safety/toxicity assessments. A current product of focus is a tumor-specific radioactive therapy designed to specifically target peritoneal metastasis of ovarian cancer. Animal studies have shown that the platform offers increased efficacy and reduced toxicity as compared to other treatment options
